Prostacyclin therapies for the treatment of pulmonary arterial hypertension.
about
The limits of oral therapy in pulmonary arterial hypertension managementRole of oxidized lipids in pulmonary arterial hypertensionOral Delivery of Protein Drugs Bioencapsulated in Plant CellsQuality of life, safety and efficacy profile of thermostable flolan in pulmonary arterial hypertensionThe safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension.Docosahexaenoic acid causes rapid pulmonary arterial relaxation via KCa channel-mediated hyperpolarisation in pulmonary hypertensionLiposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteriesTime-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation.Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.Prostanoid signaling: dual role for prostaglandin E2 in neurotoxicity.Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes.Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension.Prostacyclin: an inflammatory paradox.Prostacyclin in the intensive care setting.Diagnosis and management of pulmonary arterial hypertensionInhaled iloprost for patients with precapillary pulmonary hypertension and right-side heart failureOverview of current therapeutic approaches for pulmonary hypertension.Development of a high-affinity inhibitor of the prostaglandin transporterCentral venous line complications with chronic ambulatory infusion of prostacyclin analogues in pediatric patients with pulmonary arterial hypertension.Transition from intravenous epoprostenol to oral or subcutaneous therapy in pulmonary arterial hypertension: a retrospective case series and systematic reviewEffect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.Regulation of the human prostacyclin receptor gene by the cholesterol-responsive SREBP1.Perioperative anesthesiological management of patients with pulmonary hypertension.Arterial pulmonary hypertension in noncardiac intensive care unit.Ambrisentan for the treatment of pulmonary arterial hypertensionSteps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.Role of combination therapy in the treatment of pulmonary arterial hypertension.The management of acute pulmonary arterial hypertension.Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults.Pharmacokinetic evaluation of continuous intravenous epoprostenol.Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy.Inhaled iloprost for therapy in pulmonary arterial hypertension.Combination therapy in pulmonary arterial hypertension: do we have the right strategy?Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke.Targeted approaches to the treatment of pulmonary hypertension.Cost effectiveness of prostacyclins in pulmonary arterial hypertension.Inhaled treprostinil for the treatment of pulmonary arterial hypertension.Optimal use of treprostinil in pulmonary arterial hypertension: a guide to the correct use of different formulations.Reactive oxygen species as therapeutic targets in pulmonary hypertension.Managing an acutely ill patient with pulmonary arterial hypertension.
P2860
Q26773209-4CAEAB95-CF6B-40BA-9AB6-EACA45CBD10EQ28078566-7EB3157B-916F-498C-956A-DFF612704ABCQ28079063-6DBD7DFF-065D-40EF-825C-190666B59D37Q28544778-34998CE2-E418-446C-9CEB-CF6638299E19Q33788554-C581B148-65F7-496C-82D2-3468A30F8D0FQ33797215-A493C572-F33A-45F5-8593-C4108DF8E72AQ33890202-DCDA68E4-52D8-4938-B010-982E0515231BQ34060673-F441EA1A-5AEF-466F-B142-E0471602DCC4Q34088723-461C1D50-5DCF-4590-AEF1-AE721E0E83A1Q34954633-AB0E2CE8-4554-47B2-9B67-434B7658B897Q34985436-56EC7BCA-7556-488E-9E2E-0DB68F94EF40Q34988852-BB527C0E-5AC7-4801-873D-87A50FFF93AAQ35025863-45D55C1F-3F5D-4E62-8280-85CE6F7FEF8AQ35050464-12ED3CF1-B3B4-447F-B2A3-BA815D9022F5Q35222937-DCC5AF62-F8DD-4CA1-9F13-47FC05B628C5Q35302365-462995A2-1CC8-4130-BC77-F16559DF9A91Q35412362-25D6DB41-1AB3-4EF5-84BF-71CC7BC46058Q35429777-10BAA224-0D0A-4818-B75B-4377B6E02B68Q35665753-762DF343-ED63-4738-913A-323ACED804B0Q35895629-34C3CD30-7094-41C8-A729-CF8E80D0B4C7Q36125460-7025461A-CB9D-48C4-AF6A-3844B0F3D671Q36302755-F3CE0649-B48D-4465-AEB2-3F5A8E5B5DAFQ36336623-CAFA0BAA-4FA4-42E1-AE88-4D50702B0E41Q37019853-B274F31B-4643-4010-9246-0B2350FBEF05Q37634323-05FE7D2D-F303-4EC4-AA2E-7DF7E44AB0E4Q37705261-2951A062-6708-45D8-A0E0-A1A2BE0D64C5Q37718231-088B3D5D-BCDC-4867-9026-3939DA17B83CQ37766261-5ECF75D1-52B1-4912-8CF1-08D5E38BB3DBQ37767429-45FFBF88-E855-4BAE-BB79-8D1DEDD3D938Q37809538-4840B887-B081-4A66-BE6E-9040EECED9D3Q37860201-1BA5F571-F529-479A-A38D-8948AFAB9444Q37867662-A0A3A7A4-35F9-4D07-A310-25B287D6CDF8Q37867668-3CB86861-DC2A-44EB-9661-7DC88B1CE5B5Q37995534-FAF83CBC-4FC2-4E52-9758-6738CD981CDAQ37995985-493119CE-C73E-4472-ABB5-6F6655F1C331Q37997472-293772B8-88BA-4A54-ADC0-7320C0EE5237Q38025723-802BA31F-4D02-4018-91EF-8A0965F4F5F2Q38066529-4C7CFE0B-13D2-407F-A856-B157FD98AA37Q38074770-2CDF0C0A-D0E3-4289-975A-A14462D364A0Q38077799-23ECEC94-9398-4E6D-898A-A826BEBA949A
P2860
Prostacyclin therapies for the treatment of pulmonary arterial hypertension.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prostacyclin therapies for the treatment of pulmonary arterial hypertension.
@en
Prostacyclin therapies for the treatment of pulmonary arterial hypertension.
@nl
type
label
Prostacyclin therapies for the treatment of pulmonary arterial hypertension.
@en
Prostacyclin therapies for the treatment of pulmonary arterial hypertension.
@nl
prefLabel
Prostacyclin therapies for the treatment of pulmonary arterial hypertension.
@en
Prostacyclin therapies for the treatment of pulmonary arterial hypertension.
@nl
P1476
Prostacyclin therapies for the treatment of pulmonary arterial hypertension.
@en
P2093
M Gomberg-Maitland
P304
P356
10.1183/09031936.00097107
P577
2008-04-01T00:00:00Z